Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.50 USD
−68.25 M USD
44.76 M USD
18.78 M
About Metagenomi, Inc.
Sector
CEO
Brian C. Thomas
Headquarters
Emeryville
Website
Founded
2016
FIGI
BBG00Y5ZXS77
Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene editing toolbox, therapeutic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MGX is 2.02 USD — it hasn't changed in the past 24 hours. Watch Metagenomi, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Metagenomi, Inc. stocks are traded under the ticker MGX.
MGX stock has risen by 16.86% compared to the previous week, the month change is a 0.50% rise, over the last year Metagenomi, Inc. has showed a −80.29% decrease.
We've gathered analysts' opinions on Metagenomi, Inc. future price: according to them, MGX price has a max estimate of 25.00 USD and a min estimate of 7.00 USD. Watch MGX chart and read a more detailed Metagenomi, Inc. stock forecast: see what analysts think of Metagenomi, Inc. and suggest that you do with its stocks.
MGX stock is 5.34% volatile and has beta coefficient of 1.96. Track Metagenomi, Inc. stock price on the chart and check out the list of the most volatile stocks — is Metagenomi, Inc. there?
Yes, you can track Metagenomi, Inc. financials in yearly and quarterly reports right on TradingView.
Metagenomi, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
MGX earnings for the last quarter are −0.51 USD per share, whereas the estimation was −0.78 USD resulting in a 34.26% surprise. The estimated earnings for the next quarter are −0.75 USD per share. See more details about Metagenomi, Inc. earnings.
Metagenomi, Inc. revenue for the last quarter amounts to 11.51 M USD, despite the estimated figure of 6.76 M USD. In the next quarter, revenue is expected to reach 9.23 M USD.
MGX net income for the last quarter is −18.77 M USD, while the quarter before that showed −10.74 M USD of net income which accounts for −74.81% change. Track more Metagenomi, Inc. financial stats to get the full picture.
No, MGX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 236.00 employees. See our rating of the largest employees — is Metagenomi, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Metagenomi, Inc. EBITDA is −83.33 M USD, and current EBITDA margin is −165.98%. See more stats in Metagenomi, Inc. financial statements.
Like other stocks, MGX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Metagenomi, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Metagenomi, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Metagenomi, Inc. stock shows the strong sell signal. See more of Metagenomi, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.